Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 19/20 | 0.62 |
| ▸ | BCR | P11274 | 18/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3399556 | 0.85 | ABL1 (0.78) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL2283742 | 0.83 | NPC1 (0.52) | ABL1BCRNPC1 | |
| SCHEMBL856014 | 0.80 | MEN1 (0.78) | NPC1KDM4EMAPTMAPK1 | |
| SCHEMBL2285824 | 0.80 | ABL1 (0.61) | ABL1BCRNPC1 | |
| SCHEMBL3452003 | 0.79 | CHRNA7 (0.52) | ABL1BCRMAPT | |
| SCHEMBL6429245 | 0.79 | ABL1 (0.67) | ABL1BCR | |
| SCHEMBL26429094 | 0.78 | ABL1 (0.60) | ABL1BCRNPC1KDM4EMAPT | |
| SCHEMBL3450466 | 0.78 | ABL1 (0.79) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL22328022 | 0.78 | NPC1 (0.64) | NPC1MAPTMAPK1 | |
| SCHEMBL2174012 | 0.78 | SCN9A (0.61) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3912973-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3912973-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3536687-B1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3536687-B1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-07-14 | — | — | EP | disclosed |
| WO-2009073153-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INSTITUTE (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009073153-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INSTITUTE (US) | 2009-06-11 | — | — | WO | disclosed |
| EP-1613595-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-01 | — | — | EP | disclosed |
| US-7125997-B2 | Differential tumor cytotoxicity compounds and compositions | IRM LLC (BM) | 2006-10-24 | — | — | US | disclosed |
| CN-1798734-A | Novel compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-07-05 | — | — | CN | disclosed |
| EP-1613595-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-01-11 | — | — | EP | disclosed |
| US-20050014753-A1 | Novel compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-01-20 | — | — | US | disclosed |
| WO-2004089286-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004058713-A1 | DIFFERENTIAL TUMOR CYTOTOXOCITY COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-07-15 | — | — | WO | disclosed |
| US-20040132786-A1 | Differential tumor cytotoxicity compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | BCR, ABL1, MCL1 | ABL1 2/4885BCR 1/4885NPC1 1418/4885 |
| US-20040132786-A1 | Differential tumor cytotoxicity compounds and compositions | MIF, FOXM1, MYADM | ABL1 1482/4885BCR 3068/4885NPC1 2091/4885 |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ABL1 2/4885BCR 1/4885NPC1 1348/4885 |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | BCR, ABL1, MCL1 | ABL1 2/4885BCR 1/4885NPC1 1348/4885 |
| US-20050014753-A1 | Novel compounds and compositions as protein kinase inhibitors | ABL1, BCR, PDGFRA | ABL1 1/4885BCR 2/4885NPC1 2695/4885 |
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ABL1 2/4885BCR 1/4885NPC1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.